Category: Hormones and Midlife

Notes on hormones, perimenopause, and the midlife transition.

  • Midlife Joint Pain: Is It Perimenopause?

    Midlife Joint Pain: Is It Perimenopause?

    Beyond Hot Flashes: Why Aches, Joint Pain and Slower Recovery Deserve Attention in Perimenopause and Why HRT May Not Be Enough

    Achy knees. Stiff shoulders. Sore hips. Frequent injuries. A body that doesn’t seem to recover the way it used to.

    These are some of the surprisingly common reasons women in their 40s and 50s come into my clinic. And while we tend to associate perimenopause with hot flashes, night sweats and changes in the menstrual cycle, musculoskeletal symptoms deserve a much bigger place in the conversation.

    If it seems intuitive that shifting hormones would play a role, you might wonder why the research hasn’t established a clear causal relationship. You might also wonder why hormone therapy isn’t routinely recommended specifically for women presenting with joint and muscle pain.

    The answer is more complicated, and, I think, more interesting.

    How Common Are Midlife Muscle and Joint Aches?

    A 2026 systematic review and meta-analysis examined 37 observational studies involving more than 93,000 women. Muscle or joint pain was reported by approximately 57% of perimenopausal women, compared with 40% of premenopausal women [1].

    That’s a substantial difference, and it supports something I hear repeatedly in clinical practice: women are not imagining this change in their bodies.

    Importantly, this research establishes an association, not causation. It doesn’t tell us exactly why these symptoms develop, which tissues are affected, or how much of the change can be attributed to fluctuating or declining estrogen.

    But it does tell us that musculoskeletal symptoms are common during the menopause transition and deserve to be taken seriously.

    The Role of Estrogen and What the Research Tells Us About HRT

    Estrogen has far-reaching effects beyond reproductive health. It interacts with musculoskeletal tissues, including bone, muscle, tendons, ligaments and cartilage. It also influences inflammatory signaling and the body’s ability to maintain and repair tissue.

    It makes physiological sense, then, that changes in estrogen availability could influence how our bodies feel, move and recover.

    Clinically, I see this relationship repeatedly. In many of my patients, joint aches and stiffness are among the first symptoms to improve when we appropriately address hormonal deficiencies.

    The research, however, is more nuanced.

    In the Women’s Health Initiative randomized trial, which included more than 16,000 postmenopausal women, estrogen plus a synthetic progestin resulted in greater relief of joint pain and stiffness than placebo (47.1% versus 38.4%). Generalized aches and pains also improved more frequently with treatment (49.3% versus 43.7%) [2].

    This is meaningful evidence that hormone therapy can help, but the benefit was not universal. And these findings came from a trial of older postmenopausal women using a specific oral hormone regimen, so they cannot be assumed to predict every woman’s response to contemporary HRT.

    A more recent systematic review examining HRT and musculoskeletal pain also highlights the complexity of the evidence. This review included 57 studies and more than 3 million participants. Its pooled analysis found no significant association between ever using HRT and generalized musculoskeletal pain [3].

    So where does that leave us?

    I believe we need to stop thinking about hormones as either the answer or not the answer.

    Estrogen can be an important piece of the musculoskeletal health puzzle without being the entire puzzle.

    Why HRT Alone May Not Be Enough

    One of the things I find most important in clinical practice is recognizing that hormonal changes don’t happen in isolation.

    A woman entering perimenopause may also be experiencing changes in thyroid function, glucose regulation, body composition, muscle mass, nutritional status, sleep quality and inflammatory burden.

    All of these influence musculoskeletal health.

    Consider a few examples:

    • Thyroid function: Inadequate thyroid hormone availability can contribute to muscle aches, stiffness, weakness and impaired recovery.
    • Nutrient status: Insufficient protein, vitamin D, magnesium, iron or other essential nutrients can compromise muscle function, tissue maintenance and recovery.
    • Metabolic health: Insulin resistance and impaired glucose regulation can contribute to systemic inflammation and adversely affect musculoskeletal health.
    • Inflammation: Chronic inflammatory processes can contribute to pain, stiffness and tissue dysfunction.
    • Muscle mass and conditioning: Age-related changes in muscle mass, strength and physical conditioning can increase the mechanical demands placed on joints and connective tissues.
    • Sleep and recovery: Poor sleep disrupts tissue repair, pain regulation and the body’s ability to recover from physical stress.

    This is where looking at the whole person becomes so important.

    If you’ve started hormone therapy and aren’t seeing the improvement you expected in your aches and pains, I wouldn’t automatically conclude that hormones aren’t the answer. I would ask what else might be contributing.

    It may be time to investigate thyroid function, nutrient status, inflammatory markers and metabolic health.

    It may also be time to get honest about sleep quality, strength training, daily movement, sunlight exposure, hydration, nutritional quality and whether you’re allowing your body enough time to recover.

    These aren’t secondary considerations. They are foundational to how your body functions.

    Your Body Is Asking for More Than Symptom Management

    I want women to understand that developing aches, stiffness and slower recovery in midlife doesn’t mean they simply have to accept a new, less capable version of themselves.

    Hormonal changes matter. But so does everything that influences how your body responds to those changes.

    The research may not yet establish exactly how much hormone therapy can improve musculoskeletal symptoms in every woman, but my clinical experience has consistently reinforced the value of addressing hormonal health alongside the other physiological factors that support healthy tissue, muscle function and recovery.

    And when we don’t see the improvement we’re hoping for, that’s a reason to look deeper, not to dismiss the symptoms or assume they’re inevitable.

    My goal is never simply to make a symptom disappear. It’s to understand why it’s happening and identify what the body needs to function better.

    Remember, when you give the body what it needs and remove the obstacles standing in its way, you create the conditions for healing.

    With warmth,
    Dr. Starr

    This article is for general education only and isn’t medical advice. It doesn’t diagnose, treat, or replace care from your own licensed health care provider, and reading it doesn’t create a doctor-patient relationship. Please talk with a qualified clinician about your own symptoms and before starting, stopping, or changing any medication or supplement. If you think you have an emergency, call 911.

    References

    1. Kruse C, et al. Musculoskeletal manifestations of perimenopause: systematic review and meta-analysis of 93,021 women. JB JS Open Access. 2026;11(1). 37 observational studies. Muscle or joint pain in 57% of perimenopausal vs 40% of premenopausal women (RR 1.35); high heterogeneity. https://pubmed.ncbi.nlm.nih.gov/41523660/
    2. Barnabei VM, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women’s Health Initiative. Obstet Gynecol. 2005;105(5 Pt 1):1063-1073. RCT, n=16,608 (oral CEE + MPA). More relief of joint pain/stiffness (47.1% vs 38.4%) and general aches (49.3% vs 43.7%) than placebo; effect modest; oral regimen, not transdermal-specific. https://pubmed.ncbi.nlm.nih.gov/15863546/
    3. Overton R, Amini P, Chew A, Babatunde O, Mason KJ, Rathod S, Welsh V, Burton C. (2026). The effect of hormone replacement therapy on musculoskeletal pain in menopausal women: A systematic review and meta-analysis. Post Reproductive Health, 32(1), 52-68. https://pubmed.ncbi.nlm.nih.gov/41344380/
  • New ACOG Guidance: GLP-1 Medications Before, During and After Pregnancy

    New ACOG Guidance: GLP-1 Medications Before, During and After Pregnancy

    The American College of Obstetricians and Gynecologists, or ACOG, released new guidance in October 2026 on the use of GLP-1 receptor agonists in women who are planning pregnancy, pregnant, or breastfeeding.

    I want to walk you through the key recommendations, because the guidance is not the same at every stage.

    Preconception

    Pregnancy safety data for GLP-1 medications remain limited.

    ACOG advises considering discontinuation 1 to 2 months before conception. Weight regain is common after stopping, so this is also a time to support nutritional adequacy, healthy eating, physical activity and weight monitoring.

    Consider assessing vitamin D, vitamin B12 and ferritin status as well.

    Pregnancy

    ACOG recommends against GLP-1 use during pregnancy, except within a clinical trial.

    Human safety data remain insufficient, and animal studies have identified potential fetal growth and developmental concerns.

    If pregnancy occurs while taking a GLP-1 medication, treatment should not be continued.

    Lactation

    This recommendation is more nuanced.

    GLP-1 therapy may be considered as part of an individualized postpartum care plan through shared decision-making.

    A small human milk study found no detectable semaglutide in breast milk following subcutaneous administration at the measured time points (0, 12 and 24 hours).

    There are insufficient data regarding effects on milk volume, milk composition, infant weight gain and long-term infant outcomes.

    When treatment is indicated, ACOG suggests considering medications with a shorter half-life and identifies exenatide as a preferred consideration.

    Oral GLP-1 formulations should be avoided during breastfeeding.

    Infant weight gain should be closely monitored in coordination with the pediatric provider.

    ACOG recommends against use when breastfeeding preterm infants or neonates, meaning babies in the first 28 days of life.

    A Few Important Takeaways

    GLP-1 medications are not considered safe for use during pregnancy. However, ACOG’s new guidance recognizes that postpartum treatment decisions, particularly during lactation, require a more individualized approach.

    Importantly, limited evidence of medication transfer into breast milk is not the same as established safety. We still need more research on milk production, infant growth and long-term outcomes.

    If you are taking a GLP-1 medication and thinking about pregnancy, or if you are postpartum and considering treatment while breastfeeding, this is a conversation to have with your own clinician, who can help you weigh the available evidence in the context of your health.

    With warmth,
    Dr. Starr

    Source

    American College of Obstetricians and Gynecologists. Use of Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy and Lactation. Practice Advisory. October 2026. https://www.acog.org/clinical/guidance/practice-advisory/2026/10/use-of-glucagon-like-peptide-1-receptor-agonists-in-pregnancy-and-lactation/

  • Thyroid Health in Pregnancy and Post-Partum

    Thyroid Health in Pregnancy and Post-Partum

    WHY IS OPTIMAL THYROID FUNCTION IMPORTANT IN PREGNANCY?

    For momma: helps avoid extra fatigue, constipation and weight gain as well as postpartum depression and low milk supply

    For baby: developing babies depend on momma’s thyroid hormones for the first 20 weeks of gestation!

    Hypothyroidism in pregnancy can have some pretty scary outcomes including fetal death, maternal hypertension, preterm birth, breech delivery and low birth weight. For this reason, I take it very seriously. I recommend all newly pregnant mommas have a full thyroid panel in the first trimester. For all mommas with preexisting hypothyroidism, I monitor levels every 2-4 weeks during pregnancy and for the first 3-6 months postpartum.

    CAUSES OF HYPOTHYROIDISM IN PREGNANCY: 

    1. Estrogen increases the production of thyroid binding proteins, making the free, active hormone less bioavailable. 
    2. The placenta increases the breakdown of both T4 and T3.
    3. Increased maternal blood volume dilutes thyroid hormones.
    4. Increased maternal kidney filtration results in more iodine loss, an essential nutrient for thyroid function.

    LAB TESTING: 

    TSH: A hormone produced in the brain that tells the thyroid to produce T4, elevated in hypothyroidism

    T4: Thyroid hormone released by the thyroid gland

    T3: Made from T4 in your tissues, the most active thyroid hormone

    Simply measuring TSH is not enough in pregnancy. The hormone HCG, produced by the placenta, will partially suppress TSH. For this reason, we need to look at a complete thyroid panel that includes not only TSH, but free T4 and free T3 as well. 

    TREATMENT: 

    Medication: 

    Very little T3 crosses the placenta and so offering both T4 and T3 could lower the amount of T4 that baby receives. As a general practice, T4 alone is my choice in pregnancy, with some exceptions. If momma is stable on combination therapy before she becomes pregnant and numbers remain stable during pregnancy, it is ok to continue. 

    If free T3 is suboptimal, we focus on improving T4 to T3 conversion with therapies such as nutrients, reducing stress and limiting inflammatory foods. 

    Nutrients: 

    Thyroid hormone production and metabolism depends on iodine, selenium, zinc, vitamin D and iron. All pregnant mommas should evaluate the amounts of these nutrients in the prenatal. If the prenatal is offering much lower doses, discuss additional sources from food or supplements with your doctor if indicated. Note, most of these are maximum daily levels.

    • Iodine: 225mcg
    • Selenium: 100-200mcg 
    • Zinc: 15-25mg 
    • Vitamin D: 1,000-5,000IU 
    • Iron: dose based on lab values

    Thanks for reading! Give us a call to get your thyroid labs drawn if you’re in early pregnancy, breast-feeding or thinking about conceiving. We’re here to support you!